---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-290447"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2026-06-30T20:01:15+00:00"
generated_at: "2026-06-30T20:02:14.877262+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology appoints Scott Garland as Chairman, Michael Listgarten as General Counsel; co-founder resigns

## Summary
- Co-founder Corey Goodman resigned as Chairman and board member effective June 29, 2026, for personal reasons.
- Scott Garland, independent director since Nov 2022, appointed Chairman of the Board.
- Michael Listgarten appointed General Counsel, effective immediately.
- Company advancing evorpacept into late-stage development and progressing ALX2004.

## SEC filing metadata
- accession: 0001193125-26-290447
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2026-06-30T20:01:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312526290447/0001193125-26-290447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312526290447/alxo-20260629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-290447
- JSON: https://secwatch.observer/filing/0001193125-26-290447.json
- Plain text: https://secwatch.observer/filing/0001193125-26-290447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.